NCT05029102 2024-02-12
TAS-102 and Anlotinib in ≥3 Lines mGC
Zhejiang University
Phase 2 Unknown
Clinical Trials
23 trialsNCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT06031480 2023-09-11
FAITH
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04803851 2023-06-22
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05385900 2022-05-23
ICTCPTLAGC
Xijing Hospital
Phase NA Unknown
NCT05322499 2022-04-11
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04970914 2022-03-08
ALTER-C003
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03387904 2021-09-02
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04966611 2021-07-19
Anlotinib for Esophageal Cancer (AFEC)
Anyang Tumor Hospital
Unknown
NCT04954521 2021-07-08
AFHC
People's Hospital of Guangxi Zhuang Autonomous Region
Unknown
NCT04813406 2021-03-24
Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
Phase NA Unknown
NCT04797507 2021-03-15
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04665609 2021-03-04
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Chinese PLA General Hospital
Phase 3 Unknown
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown
NCT04764084 2021-02-21
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT04207463 2020-06-17
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT04080154 2020-04-03
ALTER-H-002
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04157140 2019-12-03
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Beijing Ditan Hospital
Phase 2 Unknown
NCT03825705 2019-10-31
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04106024 2019-09-26
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Cttq
Phase 2 Unknown
NCT03766776 2018-12-11
ATAHC
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02461407 2017-12-29
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT02809534 2016-09-07
ALTER0802
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown